Literature DB >> 8580115

A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes.

A N Singh1, C Barlas, S Singh, P Franks, R K Mishra.   

Abstract

Loxapine is a typical neuroleptic that shows great structural and functional homology to the atypical antipsychotic clozapine. Chronic loxapine treatment is usually associated with extrapyramidal symptoms (EPS), whereas clozapine treatment is not. Conversely, loxapine does not produce the agranulocytosis that often results from protracted clozapine treatment. Earlier studies of loxapine have usually implicated D2 receptor blockade as the cause of the tardive dyskinesia that occurs with chronic treatment. More recently, loxapine's ability to potentiate serotonergic neurotransmission has also been implicated. In this study, the pharmacological affinities of loxapine for the dopamine D1, D2, D4, as well as serotonin-2 (5-HT2) and NMDA receptor subtypes, were investigated through direct radioreceptor assays. The findings indicate that loxapine displays an extremely strong binding affinity for dopamine D4 and serotonin 5-HT2 receptors, which suggests that both serotonergic and dopaminergic mechanisms contribute to the antipsychotic drug action and EPS associated with loxapine in the treatment of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8580115      PMCID: PMC1188731     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  27 in total

1.  Effects of clozapine and other dibenzo-epines on central dopaminergic and cholinergic systems. Structure-activity relationships.

Authors:  H R Bürki; A C Sayers; W Ruch; H Asper
Journal:  Arzneimittelforschung       Date:  1977

Review 2.  Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs.

Authors:  R J Baldessarini; D Tarsy
Journal:  Annu Rev Neurosci       Date:  1980       Impact factor: 12.449

3.  Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.

Authors:  D R Burt; I Creese; S H Snyder
Journal:  Science       Date:  1977-04-15       Impact factor: 47.728

Review 4.  5-Hydroxytryptamine receptor subtypes in vertebrates and invertebrates.

Authors:  F Saudou; R Hen
Journal:  Neurochem Int       Date:  1994-12       Impact factor: 3.921

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine.

Authors:  A C Sayers; H R Bürki; W Ruch; H Asper
Journal:  Psychopharmacologia       Date:  1975

7.  3H-Spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylated metabolites.

Authors:  J Coupet; C E Rauh
Journal:  Eur J Pharmacol       Date:  1979-04-15       Impact factor: 4.432

8.  Aggression in the demented patient: a double-blind study of loxapine versus haloperidol.

Authors:  W Carlyle; R J Ancill; L Sheldon
Journal:  Int Clin Psychopharmacol       Date:  1993       Impact factor: 1.659

Review 9.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Authors:  D Hoyer; D E Clarke; J R Fozard; P R Hartig; G R Martin; E J Mylecharane; P R Saxena; P P Humphrey
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

10.  Animal models for tardive dyskinesia: effects of thioridazine.

Authors:  A C Sayers; H R Bürki; W Ruch; H Asper
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1977-09
View more
  11 in total

Review 1.  Novel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.

Authors:  E Stip
Journal:  J Psychiatry Neurosci       Date:  2000-03       Impact factor: 6.186

2.  Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability.

Authors:  Jessica A Hellings; Gregory Reed; Sharon E Cain; Xinghua Zhou; Francis X Barth; Michael G Aman; Gladys I Palaguachi; Dmytro Mikhnev; Rujia Teng; Rebecca Andridge; Marilyn Logan; Merlin G Butler; Joan C Han
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-03       Impact factor: 2.576

Review 3.  Alternative delivery systems for agents to treat acute agitation: progress to date.

Authors:  Kimberly Nordstrom; Michael H Allen
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

Review 4.  Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia.

Authors:  Gillian M Keating
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

5.  A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens.

Authors:  Zhu Li; Junji Ichikawa; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2003-03-28       Impact factor: 4.530

6.  Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.

Authors:  Amarendra N Singh; Cia Barlas; Huma Saeedi; Ram K Mishra
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

7.  Beneficial effects of loxapine on agitation and breathing patterns during weaning from mechanical ventilation.

Authors:  Benjamin Sztrymf; Guillaume Chevrel; Fabrice Bertrand; Dimitri Margetis; Dominique Hurel; Jean-Damien Ricard; Didier Dreyfuss
Journal:  Crit Care       Date:  2010-05-12       Impact factor: 9.097

Review 8.  The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review.

Authors:  Domenico de Berardis; Michele Fornaro; Laura Orsolini; Felice Iasevoli; Carmine Tomasetti; Andrea de Bartolomeis; Nicola Serroni; Alessandro Valchera; Alessandro Carano; Federica Vellante; Stefano Marini; Monica Piersanti; Giampaolo Perna; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Int J Mol Sci       Date:  2017-02-08       Impact factor: 5.923

9.  The in Vitro Actions of Loxapine on Dopaminergic and Serotonergic Receptors. Time to Consider Atypical Classification of This Antipsychotic Drug?

Authors:  Florian Ferreri; Dominique Drapier; Emmanuelle Baloche; Mehemed Ouzid; Luc Zimmer; Pierre-Michel Llorca
Journal:  Int J Neuropsychopharmacol       Date:  2018-04-01       Impact factor: 5.176

Review 10.  Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

Authors:  Justin Faden; Leslie Citrome
Journal:  Neuropsychiatr Dis Treat       Date:  2019-08-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.